CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Jonan-ku, Fukuoka-shi, Japan

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

    Phase

    3

    Span

    172 weeks

    Sponsor

    argenx

    Fukuoka

    Recruiting

  • Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER)

    Phase

    1/2

    Span

    71 weeks

    Sponsor

    UNB Sumiyoshi Jinja Mae Clinic

    Fukuoka

    Recruiting

  • Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries

    Up to 60 subjects at up to 10 sites in Japan will be enrolled in the femoropopliteal clinical study with moderate and severely calcified femoropopliteal artery disease presenting with Rutherford Category 2 - 5 of the target limb. Two additional cohorts [Iliac and BTK (Below-the-Knee)] will enroll a minimum of 10 and a maximum of 15 subjects each with moderate and severely calcified iliac disease with a Rutherford Category (RC) 2 - 5 and a minimum of 10 and a maximum of 15 subjects with moderate and severely calcified BTK lesions with a Rutherford Category (RC) 2 - 5 will be enrolled and followed through 12 months. The estimated study duration for these cohorts is approximately 24 months. Study subjects will be followed through discharge, 30 days, 6, and 12 months.

    Phase

    N/A

    Span

    156 weeks

    Sponsor

    Shockwave Medical, Inc.

    Fukuoka

    Recruiting

  • Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

    Pediatric participants will be enrolled as follows: - Cohort 1: Infants and children from 4 weeks postnatal age, weighing ≥ 1.5 kg to < 40 kg - Cohort 2: Neonates, either born at term or preterm, weighing ≥ 1.5 kg to < 6 kg

    Phase

    2

    Span

    61 weeks

    Sponsor

    Gilead Sciences

    Fukuoka

    Recruiting

  • A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    Phase

    3

    Span

    374 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Fukuoka

    Recruiting

  • A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

    This trial will evaluate the safety and efficacy of valemetostat tosylate (DS-3201b) in combination with fixed-dose pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic NSCLC without actionable genomic alterations, whose tumor has PD-L1 TPS ≥50%, and who have not received prior systemic therapy for advanced or metastatic NSCLC. The trial will be in 2 phases, dose escalation and dose expansion phases.

    Phase

    1/2

    Span

    287 weeks

    Sponsor

    Daiichi Sankyo

    Fukuoka

    Recruiting

  • A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

    Phase

    2

    Span

    87 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Fukuoka

    Recruiting

  • A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

    Phase

    3

    Span

    147 weeks

    Sponsor

    UCB Biopharma SRL

    Fukuoka

    Recruiting

  • Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

    Phase

    2

    Span

    81 weeks

    Sponsor

    AbbVie

    Fukuoka

    Recruiting

  • Software as a Medical Device for the Treatment of Patients With PTSD

    Phase

    2/3

    Span

    179 weeks

    Sponsor

    Otsuka Medical Devices Co., Ltd. Japan

    Fukuoka

    Recruiting

1-10 of 184
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information